每经AI快讯，康美药业（SH 600518，收盘价：1.97元）12月10日晚间发布公告称，公司第十届2025年 度第五次董事会临时会议于2025年12月10日以现场结合通讯表决方式召开。会议审议了《关于修订 <董 事会议事规则> 的议案》等文件。 每经头条（nbdtoutiao）——最新1520元，飞天茅台批价两年跌了43%，经销商躺赢神话破灭，当潮水 退去谁在裸泳？ （记者 曾健辉） 2024年1至12月份，康美药业的营业收入构成为：医药占比81.73%，其他行业占比9.1%，保健食品及食 品占比8.43%，其他业务占比0.74%。 截至发稿，康美药业市值为272亿元。 ...

Core Insights - Tian Da Group has announced a dual-driven strategy focusing on "pharmaceutical health + fine phosphorus chemical" to enhance its industrial layout in Yunnan, marking a new phase of collaborative development and upgrade [1][5] Group Strategy - The company plans to deepen its pharmaceutical health industry layout in Yunnan, leveraging the region's unique biological resources as a key support for Tian Da Pharmaceutical's development [3] - Tian Da Pharmaceutical will implement a quality management system called "Tian Da Standard" to ensure product quality from the source of traditional Chinese medicine to the consumer end, with increased systematic investment in local medicinal materials [3] Product Development - The product matrix of Tian Da Pharmaceutical covers critical therapeutic areas such as cardiovascular, pediatrics, respiratory, anti-infection, and anti-tumor, with established brands like "He Gu" and "Tuo Kang" [3] - The company aims to promote high-quality products and services originating from Yunnan to national and global markets through its online and offline health service platform, "Tian Da Pavilion" [3] Phosphorus Chemical Industry - The fine phosphorus chemical sector will also be developed, with plans to invest in high-value-added projects based on the Xundian phosphorus mine, targeting the creation of a billion-level industrial cluster to assist in the transformation and upgrading of Yunnan's local industry [5] Commitment to Health - The chairman emphasized that the motto "Your health is a big deal for Tian Da" reflects the company's commitment to transforming Yunnan's ecological and resource advantages into high-quality health products and industrial momentum [5]

Group 1 - The Hang Seng Index fell by 0.43%, down 109 points, closing at 25,324 points, while the Hang Seng Tech Index decreased by 0.68% [1] - Lithium carbonate futures for the 2605 contract rose over 3%, reaching a peak of 96,800 yuan/ton, leading to gains in lithium stocks such as Ganfeng Lithium, which increased by 3.16%, and Tianqi Lithium, which rose by over 2% [1] - China Molybdenum's stock price increased by over 5% as CICC remains optimistic about the tungsten price bull market [2] Group 2 - Silver Star Pharmaceuticals-B surged over 18% after the company successfully entered the insurance market with its GLP-1 receptor agonist, Eino Light® [3] - Gold stocks generally rose, with Zijin Mining International increasing by over 4% and Lingbao Gold rising by 9%, supported by a strong gold market ahead of the Federal Reserve's decision [3] - Baoji Pharmaceutical-B debuted with a significant increase of 124% on its first trading day, with three core products set to be commercialized soon [4] Group 3 - China Boton saw its stock price rise by over 13% after signing a land acquisition agreement, which will provide cash compensation of 2.272 billion yuan [5] - Red Star Macalline's stock increased by over 6% as the company deepens strategic cooperation with Zuo You Home to explore new retail transformation paths [6] - China Metallurgical Group's stock continued to decline by 3.72%, following a significant drop of over 21% the previous day after announcing plans to sell assets worth 60.7 billion yuan [7] Group 4 - Pacific Basin Shipping's stock fell by over 9% as the Baltic Dry Index dropped to a near two-week low [8] - Smoore International's stock decreased by over 8%, having halved from its year-to-date high, as major client British American Tobacco forecasted performance pressures for the next year [9]

Group 1 - The Hang Seng Index opened flat, while the Hang Seng Tech Index fell by 0.04%. Notably, tech stocks were active with Meituan rising by 1.08% and Baidu Group increasing by 0.91%. In the pharmaceutical sector, Fosun Pharma surged by 4.19% [1] - Haitong International believes that after market consolidation, a rebound is expected to continue, with room for tech recovery. The firm suggests that the rebound's strength will depend on policy implementation and potential interest rate cuts by the Federal Reserve. There is a caution regarding the risk of profit-taking if the market anticipates good news too early [1] - Everbright Securities indicates that after a rebound in 2025, the current valuation of the Hang Seng Index is above its 5-year average, reflecting a reasonable valuation range. The tech index has just returned to its 5-year average, suggesting there is still room for valuation catch-up. The firm predicts that the Hang Seng Index could exceed 30,000 points next year [1] Group 2 - Guotai Junan Securities states that the short-term adjustment in the Hong Kong stock market opens up space for a market rise in 2026. In terms of capital flow, over 110 billion RMB of southbound funds have net flowed into the Hong Kong stock market in November. This indicates strong liquidity and a strong willingness from mainland investors to position themselves in the Hong Kong market at lower levels [2] - The firm forecasts that the Hong Kong stock market could operate between 30,000 and 32,000 points in 2026 [2]

Market Overview - The Hong Kong stock market indices declined again, with the Hang Seng Index falling 1.29% to 25,434.23 points and a total trading volume of HKD 210.236 billion [1] - The decline in the Hong Kong market is attributed to several factors, including a shrinking southbound capital flow, concerns over potential interest rate hikes by the Bank of Japan, and expectations that the Federal Reserve's upcoming rate cut may not be as dovish as anticipated [1] Blue Chip Performance - WuXi Biologics (02269) led the blue-chip stocks, rising 1.88% to HKD 33.56, contributing 3.64 points to the Hang Seng Index [2] - Other notable blue-chip performances included China Biologic Products (01177) up 1.33% and WuXi AppTec (02359) up 1.06%, while Xinyi Glass (00868) fell 8.11% and Chow Tai Fook (01929) dropped 4.82% [2] Sector Movements - Large technology stocks experienced declines, with Alibaba down 1.63% and Tencent down 0.41%. Chip stocks fell collectively after the announcement allowing NVIDIA to sell H200 chips to China, with SMIC down over 4% [3][5] - The real estate sector saw significant declines, particularly with Agile Group (03383) dropping 18.42% amid a court liquidation petition [4] - Industrial metals stocks, including Jiangxi Copper (00358) and China Aluminum (02600), faced notable declines, with Jiangxi Copper down 6.51% [3][4] Notable Company Developments - China Metallurgical Group (01618) saw a significant drop of 21.01% after announcing a cash transaction to sell its subsidiaries for approximately HKD 60.7 billion [6] - Gilead Sciences (01672) surged 18% following positive results from a clinical trial for its obesity treatment, with Citigroup expecting a positive market reaction [7] - E-Hi Auto (02858) rose 10.67% after renewing a strategic cooperation agreement with Tencent's subsidiary for used car services [8]

1. 有色金属股跌幅居前。截至收盘，江西铜业（600362）股份(00358)跌6.51%，报33.58港元；洛阳钼业 （603993）(03993)跌6.42%，报17.92港元；中国铝业（601600）(02600)跌5.69%，报10.77港元；紫金矿 业（601899）(02899)跌4.24%，报32.5港元。 盘面上，大型科技股悉数下跌，阿里巴巴跌1.63%，腾讯跌0.41%。特朗普宣布允许英伟达对华出售 H200芯片，芯片股集体走低，中芯国际跌超4%，数据中心股万国数据则涨超2%；内房股普遍下行，雅 居乐集团跌超18%；水泥、钢铁、石油、航空股等承压。另一边，部分医药股逆势走强，歌礼制药 ASC30治疗肥胖症的13周II期研究取得积极顶线结果，股价劲升18%。 市场预计日本央行将调整加息步伐；欧洲央行执委Schnabel的鹰派讲话，促使市场押注明年加息；美联 储影子主席哈塞特发表的不够鸽派的言论，同样打压明年降息预期。分析人士指出，市场几乎已消化美 联储本周降息的预期，但投资者认为其政策声明和主席鲍威尔的讲话可能暗示进一步降息的门槛提高。 市场等待本周美联储议息会议，港股三大指数今日再度走低，恒 ...

智通财经12月9日讯（编辑 胡家荣）今日港股市场表现疲弱，三大指数全线收跌。截至收盘，恒生指数跌1.29%，报25434.23点；恒生科技指数跌1.90%，报 5554.68点；国企指数跌1.62%，报8936.41点。 注：恒生指数的表现 尽管当前港股市场持续承压，但是招商证券指出，2026年港股核心驱动力将转向"新供给创造新需求"的新范式。这一转变源自科技创新加速、产业转型升级 以及财政模式优化，为市场提供坚实支撑。叠加中美流动性双宽松环境与当前估值洼地优势，他们预测恒生指数2026年有望实现10%-15%的温和上行，呈 现"慢牛"格局。 截至收盘，江西铜业股份(00358.HK)跌6.51%、洛阳钼业(03993.HK)跌6.42%、中国铝业(02600.HK)跌5.69%。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 * | | --- | --- | --- | --- | --- | | 00661 | 中国大冶有色金属 | 0.093 | -0.010 | -9.71% | | 00358 | 江西铜业股份 | 33.580 | -2.340 | -6.51% | | 03993 | ...

海翔药业（002099）(002099.SZ)公告，公司与国科大杭州高等研究院(简称"杭高院")签署了《共建先进 合成技术产业研究院合作协议》，产业研究院的研发方向主要聚焦医药原料药、中间体、染料、新材料 的开发与工业化等，合作总金额5000万元。 ...

12月9日，沪深两市主要股指小幅回调。截至9点55分，A500ETF南方(159352.SZ)小幅回调，热门个股 中，胜宏科技涨超5%，中国船舶、中际旭创、新易盛等涨超4%，中兴通讯、恒瑞医药等涨超2%。 消息面上，12月8日，中共中央政治局召开会议，分析研究2026年经济工作。会议总结分析今年经济工 作，对明年经济工作作出一系列重要部署，必将进一步坚定发展信心、凝聚发展共识，有效应对各种冲 击挑战，巩固拓展经济稳中向好势头，为实现"十五五"良好开局打牢基础。 中信证券指出，会议为2026年实现"十五五"良好开局提出若干政策着力方向：一是继续实施更加积极的 财政政策和适度宽松的货币政策，新增"发挥存量政策和增量政策集成效应"，我们预计总量政策或更注 重效能。二是坚持内需主导，预计明年的政策重心也可能逐渐从聚焦供给更多向需求平衡，推动促内需 和惠民生相结合。三是坚持创新驱动，我们建议关注集成电路、工业母机、高端仪器等重点领域的超常 规措施出台。四是坚持改革攻坚，我们预计在统一大市场、畅通公用事业价格疏导、加大民间投资等领 域释放经济活力。 中证A500指数作为覆盖A股新经济龙头的重要宽基指数，行业分布均衡，相比 ...

Core Viewpoint - The company plans to issue A-shares to a specific entity, Jiangyao Holdings, to strengthen its capital structure and control, while also enhancing its operational capabilities in the pharmaceutical industry. Group 1: Issuance Overview - The issuance of A-shares has been approved by the company's board and requires further approvals from shareholders, regulatory bodies, and exchanges before implementation [4][33]. - Jiangyao Holdings will subscribe to the shares for cash, constituting a related party transaction, with independent directors having reviewed the transaction [4][31]. - The maximum number of shares to be issued is 74,605,216, representing 13% of the company's total share capital before the issuance [6][23]. Group 2: Financial Details - The issuance price is set at 6.09 yuan per share, which is at least 80% of the average trading price over the previous 20 trading days [5][21]. - The total funds raised from this issuance are expected to be no more than 454,345,765.44 yuan, which will be used to supplement working capital and repay interest-bearing debts [6][25]. - The issuance will not affect the company's compliance with listing requirements regarding share distribution [34]. Group 3: Strategic Purpose - The issuance aims to consolidate the control of Jiangyao Holdings, which will hold approximately 19.23% of the company post-issuance, thereby optimizing the shareholding structure [14][58]. - The funds raised will enhance the company's financial strength and risk resistance, providing a solid foundation for future business expansion [16][58]. - The collaboration with Jiangyao Holdings is expected to improve market penetration and sales of existing products, leveraging their distribution channels [15][58]. Group 4: Market Context - The pharmaceutical industry is experiencing growth due to increased government support and rising healthcare demands driven by an aging population and higher health awareness [12][13]. - The CRO market in China is projected to grow significantly, with a compound annual growth rate of approximately 14% from 2022 to 2030, indicating strong future demand [13].